Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONTPARK_OLE extension trial of montelukast in mild-moderate Parkinson’s disease
2026-525906-37-00Phase 3Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of montelukast in Parkinson's disease (PD), sponsored by Karolinska University Hospital. Primary endpoint: Safety (adverse events and laboratory abnormalities). Planned start Jun 2026; status: authorised.
02
Drugs
montelukast
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2026-525906-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525906-37-00.